Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Breast Neoplasms
/ drug therapy
Chemotherapy, Adjuvant
/ adverse effects
Cyclophosphamide
/ administration & dosage
Docetaxel
/ administration & dosage
Female
Humans
Paclitaxel
/ administration & dosage
Retrospective Studies
breast cancer
chemotherapy
elderly
Journal
The breast journal
ISSN: 1524-4741
Titre abrégé: Breast J
Pays: United States
ID NLM: 9505539
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
29
09
2018
revised:
05
10
2018
accepted:
11
10
2018
pubmed:
11
5
2019
medline:
14
1
2020
entrez:
11
5
2019
Statut:
ppublish
Résumé
Adjuvant chemotherapy with docetaxel/cyclophosphamide (TC) is adopted worldwide as a valuable option for elderly patients with high-risk early breast cancer. Some studies suggest that paclitaxel may have a better therapeutic ratio than docetaxel. Therefore we have implemented an adjuvant chemotherapy in which docetaxel was replaced by paclitaxel. We report here the retrospective analysis of that cohort and make a safety comparison with an earlier TC cohort in the same target population. This retrospective analysis demonstrates the feasibility of paclitaxel/cyclophosphamide as an alternative, better tolerated adjuvant regimen for elderly patients. Further evaluation and assessment of noninferiority to TC is warranted.
Substances chimiques
Docetaxel
15H5577CQD
Cyclophosphamide
8N3DW7272P
Paclitaxel
P88XT4IS4D
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
663-666Informations de copyright
© 2019 Wiley Periodicals, Inc.